Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference

CHARLOTTE, N.C., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET...
November 17, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces FDA Acceptance of NDA for Filing and Designation of Priority Review of NORTHERA(TM) for the Treatment of Symptomatic NOH

CHARLOTTE, N.C., Nov. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New...
November 02, 2011 16:15 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Third Quarter 2011 Results

CHARLOTTE, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2011 and presented a quarterly update on the...
November 02, 2011 16:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Preliminary Results of Interim Analysis of CH-4051 Phase II Trial in Rheumatoid Arthritis

Mid-Range Dose of CH-4051 Demonstrates Similar Comparable Efficacy and Improved Safety and Tolerability Compared to Standard Dose of Methotrexate Data From 0.3 mg and 1.0 mg CH-4051 Arms Suggest...
October 27, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2011 Results

CHARLOTTE, N.C., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2011...
September 28, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Submits New Drug Application for NORTHERA(TM) (droxidopa) for the Treatment of Symptomatic NOH

CHARLOTTE, N.C., Sept. 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug...
September 07, 2011 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the 13th Annual Rodman & Renshaw Global Healthcare Investment Conference

CHARLOTTE, N.C., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual Rodman & Renshaw Global Healthcare Investment...
September 06, 2011 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Receives New Patent for Use of Droxidopa in Fibromyalgia

CHARLOTTE, N.C., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that the United States Patent and Trademark Office has issued U.S. Patent No....
August 10, 2011 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the Wedbush 2011 Life Sciences Management Access Conference

CHARLOTTE, N.C., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Wedbush 2011 Life Sciences Management Access Conference at...
August 08, 2011 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia

CHARLOTTE, N.C., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of...